<DOC>
	<DOCNO>NCT02354417</DOCNO>
	<brief_summary>This open-label , safety study single ProHema-CB product administer follow myeloablative condition regimen pediatric subject hematologic malignancy .</brief_summary>
	<brief_title>A Phase 1 Trial Single ProHema® CB Product Pediatric Patients With Hematologic Malignancies</brief_title>
	<detailed_description>A maximum 18 eligible male female subject ( 1 18 year old , inclusive ) enrol treated trial approximately 3 5 center within U.S . These 18 subject consist 3 cohort 6 subject . The cohort define age : 1 4 year ; &gt; 4 12 year ; &gt; 12 18 year . These cohort enrol simultaneously . All subject admit hospital , per institutional practice , receive myeloablative conditioning regimen , receive HLA-matched partially match ProHema-CB unit study Day 0 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Male female subject age 1 18 year , inclusive . 2 . Subjects hematologic malignancy allogeneic stem cell transplantation deem clinically appropriate . 1 . Acute Myelogenous Leukemia ( AML ) high risk 1st subsequent CR 2 . Acute Lymphoblastic Leukemia ( ALL ) CR 3 . NK cell lymphoblastic leukemia CR 4 . Biphenotypic undifferentiated leukemia 1st subsequent CR 5 . Myelodysplastic Syndrome ( MDS ) stage . 6 . Chronic Myelogenous Leukemia ( CML ) All subject evidence CNS leukemia must treat CNS CR eligible trial . 3 . Lack 5 6/6 HLA match related 8/8 HLA A , B , C , DRß1 match unrelated donor ; unrelated donor available within appropriate timeframe , determine transplant physician . 4 . Availability suitable primary secondary umbilical cord blood ( UCB ) unit . 5 . Adequate performance status , define : 1 . Subjects ≥ 16 year : Karnofsky score ≥ 70 % . 2 . Subjects &lt; 16 year : Lansky score ≥ 70 % . 6 . Cardiac : Left ventricular ejection fraction rest must &gt; 40 % , shorten fraction &gt; 26 % . 7 . Pulmonary : 1 . Subjects &gt; 10 year : DLCO ( diffusion capacity ) &gt; 50 % predict ( correct hemoglobin ) 2 . FEV1 , FVC &gt; 50 % predict ; Note : If unable perform pulmonary test , O2 saturation &gt; 92 % room air . 8 . Renal : Serum creatinine within normal range age , serum creatinine outside normal range age , renal function ( creatinine clearance GFR ) &gt; 70mL/min/1.73m2 . 9 . Hepatic : Bilirubin ≤ 2.5 mg/dL ( except case Gilbert 's syndrome ongoing hemolytic anemia ) ; ALT , AST Alkaline Phosphatase ≤ 5 × ULN . 10 . Signed IRB approve Informed Consent Form ( ICF ) . 1 . Female subject pregnant breastfeeding . 2 . Evidence HIV infection HIV positive serology . 3 . Current uncontrolled bacterial , viral fungal infection . 4 . Prior allogeneic hematopoietic stem cell transplant . 5 . Autologous transplant &lt; 12 month prior enrollment . 6 . Prior autologous transplant disease UCB transplant perform . 7 . Active malignancy one UCB transplant perform within 12 month enrollment . 8 . Inability receive TBI . 9 . Requirement supplemental oxygen . 10 . HLAmatched related donor able donate . 11 . Use investigational drug within 30 day prior screen . 12 . Subject unlikely comply protocol requirement , instruction studyrelated restriction</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>